Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK5764227 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Metastatic colorectal cancer (mCRC) cohort A1 | EXPERIMENTAL | - |
| Metastatic colorectal cancer (mCRC) cohort A2 | EXPERIMENTAL | - |
| Metastatic castration-resistant prostate cancer (mCRPC) cohort B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GSK5764227 | DRUG | Participants will receive GSK5764227. |
| Bevacizumab | DRUG | Participants will receive bevacizumab. |
| Fluorouracil | DRUG | Participants will receive fluorouracil. |
| leucovorin | DRUG | Participants will receive leucovorin. |
| Enzalutamide | DRUG | Participants will receive enzalutamide. |
Inclusion Criteria: * Has an ECOG performance status of 0 or 1, with no deterioration in the 2 weeks before first dose. * Has adequate organ function. * Has histologically confirmed unresectable adenocarcinoma or unresectable metastatic adenocarcinoma of the colon or rectum. (Cohort A) * Histologic...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
GSK5764227 is an investigational small molecule being developed for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is currently being studied in patients with advanced solid tumors as part of a Phase 1 clinical trial.
GSK5764227 is being developed by GSK plc, a global biopharma company listed on the London Stock Exchange under the ticker GSK. The company is conducting a Phase 1 clinical trial to evaluate the drug in combination with standard of care or other agents in participants with advanced solid tumors.
GSK5764227 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being tested for safety and efficacy in humans. The ongoing Phase 1 trial is currently recruiting participants.
GSK5764227 is being studied in a Phase 1 clinical trial with the identifier NCT07277270. This trial is titled 'A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors' and is currently recruiting participants in the United States, Australia, and Spain.
The Phase 1 trial of GSK5764227 (NCT07277270) has a planned enrollment of 84 participants aged 18 years and older. The trial is controlled but not randomized or double-blinded. It is open to all sexes and does not involve healthy volunteers.